The market for cell therapy manufacturing worldwide is forecasted to be priced at US$ 3,755.4 million in the year 2022 and is anticipated to show a CAGR of 15.2% in the predicted period from 2022 to 2030 as reported in a newly published report by Coherent Market Insights.
Cell therapy product manufacturers’ candidates are involved in obtaining controlling consents to increase their manufacturing process of the cell therapy, which is anticipated to push the market growth of cell therapy manufacturing worldwide. For example, a subsidiary of Gilead Company, Kite, in April 2022, declared that the United States Food and Drug Administration (USFDA), had consented its CAR T-Cell therapy Yescarta (axicabtagene ciloluecel), for adult patients who are having large B-cell lymphoma that is rebellious to first line of chemoimmunotherapy or which relapses within 12months of first-line chemoimmunotherapy.
Furthermore, the U.S FDA in March 2022, consented Janssen Pharmaceutical Companies’ CAR T Cell Therapy ciltacabtagene autoleucel (Carvykti; cilta-cel) in treating patients’ with relapsed multiple myeloma.
Request Sample Report (Including Full TOC, Table & Figures) @
Astellas Pharma Inc., is a pharmaceutical company that pronounced its collaboration with Minovia Therapeutics, Ltd., a medical-stage international biotechnology company on July 30th, 2021. The collaboration aimed at the R&D activities and the commercialization of the new cell therapy drivers for ailments which are caused by mitochondrial dysfunction.
An analytical laboratory equipment producing company, Thermo Fisher Scientific in August 4, 2022, declared it expansion of cell culture media manufacturing site in Grand Island, New York to encounter the rising need for cell culture media worldwide needed in producing novel vaccines and biologics.
However, rising prevalence of vitiligo across the globe is anticipated to push the market of the CTM worldwide in the predicted period. For example, as per National Center for Biotechnology Information, 2021, Vitiligo is a type of pigmentation disordered that has acquired of unknown origin and it is the most common case of depigmentation, which has its cause of incidence ranging from 0.5 to 2% across the world in 2020. Cells of the stem are needed in treating many skin diseases like vitiligo and more.
The pandemic of COVID_19 and the nationwide lockdown in many countries worldwide have affected the financial condition of the business houses in all the sectors, which included the healthcare sector that are privately owned. The pandemic affected the whole healthcare industries’ supply chain owing to the stringent lockdown in many regions. Privately owned healthcare industry is the industry which got severely impacted by the coronavirus.
Furthermore, the COVID-19 and its outbreak had a positive effect on the cell therapy manufacturing market, due to the rising efforts by the main companies in the market to create COVID-19 vaccines for the infection. For example, in November 2021, as per an article issued by Frontiers Media S.A, stem cell therapy revealed a positive impact on reduction of patients’ mortality and morbidity with COVID-19. Furthermore, main players functioning in the market emphasizes on developing treatment of COVID-19 by means of cell therapy and thus, are emphasizing on getting controlling consent for its application. For example, the U.S Food and Drug Administration in April 2022, declared the clearance of BioCardia’s Investigational New Drug (IND) application to start a Phase I/II medical trial of BCDA-04 among adults who are recovering from COVID-19 associated acute respiratory distress syndrome (ARDS).
Therefore, rising efforts by the main companies in developing vaccines and in carrying out R&D (research and activities) for COVID-19 infection is anticipated to push the growth of the market in the predicted period.
Get PDF Brochure with Latest Insights @
Globally, the market for cell therapy manufacturing is anticipated to show a CAGR of 15.2% in the predicted period owing to the rising use of strategies adopted like partnership with the main companies. For example, an analytical laboratory instrument producing company named Thermo Fisher Scientific and the University of California, San Francisco (UCSF) on May 19th, 2021, pronounced their formation of strategic partnership to increase in developing and producing of cell-based therapies.
Based on the source, the segment of induced pluripotent stem cell (IPSC) is forecasted to hold a dominating place in the market of CTM worldwide in the predicted period, due to expansion facility for manufacturing IPSC’s. For example, March 15th, 2022, a contract development and manufacturing organization (CDMO), I Peace, Inc., which specializes in IPSC’s, expanded the manufacturing facility, triple folding the biotech startup’s ability to produce IPSC cells. This facility is to pass through a governing review and a U.S.FDA registration up gradation. The facility started its operation from April 2022.
Based on regions, North America is forecasted to report for the major portion of the share in the market of CTM worldwide in the predicted period, due to the rise in figure of consents for manufacturing by governing bodies. For example, a biopharmaceutical company Kite Pharma and subsidiary of Gilead Science Company, also a biopharmaceutical company declared its receive of consent for commercial production at the new company’s CAR-T cell therapy manufacturing facility in Frederick, Maryland by the United States FDA (Food and Drug Administration). The site will be engaged in producing Kite’s FDA cleared CAR-T cell therapy in the treatment of blood cancer.
The main companies functioning in the market of CTM worldwide are WuXi AppTec, Inc., Lineage Cell Therapeutics, Inc., HEALIOS K.K., Lonza, Merck KGaA., Takara Bio Inc., Sumitomo Dainippon Pharma Co., LTD, Fujifilm Holdings Corporation, Thermo Fisher Scientific, Inc., Astellas Pharma Inc.
Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/1728
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Cell Therapy Manufacturing Market Size Analysis from 2022 to 2030
11.6 COVID-19 Outbreak: Cell Therapy Manufacturing Industry Impact
Chapter 2 Global Cell Therapy Manufacturing Competition by Types, Applications, and Top Regions and Countries
2.1 Global Cell Therapy Manufacturing (Volume and Value) by Type
2.3 Global Cell Therapy Manufacturing (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Cell Therapy Manufacturing Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Cell Therapy Manufacturing Market Analysis
Chapter 6 East Asia Cell Therapy Manufacturing Market Analysis
Chapter 7 Europe Cell Therapy Manufacturing Market Analysis
Chapter 8 South Asia Cell Therapy Manufacturing Market Analysis
Chapter 9 Southeast Asia Cell Therapy Manufacturing Market Analysis
Chapter 10 Middle East Cell Therapy Manufacturing Market Analysis
Chapter 11 Africa Cell Therapy Manufacturing Market Analysis
Chapter 12 Oceania Cell Therapy Manufacturing Market Analysis
Chapter 13 South America Cell Therapy Manufacturing Market Analysis
Chapter 14 Company Profiles and Key Figures in Cell Therapy Manufacturing Business
Chapter 15 Global Cell Therapy Manufacturing Market Forecast (2022-2030)
Chapter 16 Conclusions
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
533 Airport Boulevard, Suite 400,
Burlingame, CA 94010, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027